Standout Papers

Incidence of Endocrine Dysfunction Following the Use of Different Immune C... 2014 2026 2018 2022 744
  1. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens (2017)
    Romualdo Barroso‐Sousa, William T. Barry et al. JAMA Oncology
  2. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer (2015)
    Sara M. Tolaney, William T. Barry et al. New England Journal of Medicine
  3. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study (2014)
    Joyce F. Liu, William T. Barry et al. The Lancet Oncology

Immediate Impact

12 by Nobel laureates 8 from Science/Nature 65 standout
Sub-graph 1 of 21

Citing Papers

Therapeutic resistance to anti-oestrogen therapy in breast cancer
2023 Standout
Ferroptosis regulation by the NGLY1/NFE2L1 pathway
2022 StandoutNobel
6 intermediate papers

Works of William T. Barry being referenced

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
2018
Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
2012
and 5 more

Author Peers

Author Last Decade Papers Cites
William T. Barry 4207 2320 1544 2111 189 8.2k
Salomon M. Stemmer 4877 1630 1595 1993 236 8.3k
M. Kaufmann 3499 2406 812 1624 241 6.3k
Helena Earl 3415 2001 1232 1871 191 6.3k
Christian F. Singer 2920 2002 954 1980 262 6.2k
Maura N. Dickler 6313 2741 3212 3363 164 10.3k
Jacques De Grève 3427 1256 1755 3149 261 8.1k
Vesa Kataja 3865 2222 2088 2308 174 8.7k
Bernard Têtu 2667 1437 2289 2610 195 8.2k
Angelo Paradiso 2892 1965 1022 3787 327 7.6k
Isabella Sperduti 3918 1344 2294 2138 391 8.8k

All Works

Loading papers...

Rankless by CCL
2026